Cita APA (7a ed.)
Biswas, S., Srivastava, Y., Falodia, R., & Hamadttu, A. (2026 Supplement 19). Real-world comparative safety of first-line lorlatinib versus alectinib in metastatic ALK-rearranged non-small cell lung cancer: A propensity score-matched analysis. Journal of Clinical Oncology, 44, 283-310.
Cita Chicago Style (17a ed.)
Biswas, Shankar, Yashasvi Srivastava, Rahul Falodia, y Ayman Hamadttu. "Real-world Comparative Safety of First-line Lorlatinib Versus Alectinib in Metastatic ALK-rearranged Non-small Cell Lung Cancer: A Propensity Score-matched Analysis." Journal of Clinical Oncology 44 (2026 Supplement 19): 283-310.
Cita MLA (9a ed.)
Biswas, Shankar, et al. "Real-world Comparative Safety of First-line Lorlatinib Versus Alectinib in Metastatic ALK-rearranged Non-small Cell Lung Cancer: A Propensity Score-matched Analysis." Journal of Clinical Oncology, vol. 44, 2026 Supplement 19, pp. 283-310.
Precaución: Estas citas no son 100% exactas.